A Phase II Study of Enzalutamide in Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian Cancer

Protocol
13-119
Full Title
A Phase II Trial of Enzalutamide in Patients with Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Phase
II
Purpose

Enzalutamide (MDV3100) is a drug that blocks the hormone testosterone from binding to a protein on cells called the androgen receptor. It is approved for the treatment of men with advanced prostate cancer. Researchers believe that blocking the androgen receptor may also slow or stop tumor growth in patients with ovarian, fallopian tube, or primary peritoneal cancers that contain the androgen receptor.

In this study, researchers are evaluating the safety and effectiveness of enzalutamide for the treatment of women with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancers that contain the androgen receptor. Enzalutamide is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have ovarian, fallopian tube, or primary peritoneal cancer that has come back or continued to grow despite at least one but no more than three prior regimens of treatment.
  • At least one previous treatment should have included a platinum-containing drug.
  • Patients should have recovered from the serious side effects of previous treatment before entering the study.
  • This study is open to patients ages 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Rachel Grisham at 646-888-4653.

Disease(s)
Related Diseases